The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Is non-HD–MTX based, dose-dense, combination chemotherapy a valid choice in osteosarcoma in developing world?
Jyoti Bajpai
No relevant relationships to disclose
Chandrakanth MV
No relevant relationships to disclose
Nishitha Shetty
No relevant relationships to disclose
Jaya Ghosh
No relevant relationships to disclose
Bharat Rekhi
No relevant relationships to disclose
Tushar Shailesh Vora
No relevant relationships to disclose
N. A. Jambhekar
No relevant relationships to disclose
Nehal Rishi Khanna
No relevant relationships to disclose
Shripad Dinanath Banavali
No relevant relationships to disclose
Sudeep Gupta
No relevant relationships to disclose